Hi

The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all worthwhile. We’re thrilled to share that MB22001 is showing exceptional promise in addressing depression with fewer side effects compared to traditional antidepressants and we now eagerly await the results from our recently completed Phase 2B trial in patients with Major Depressive Disorder.

Discover More!

Results from our Phase 1 RCT and Phase 2A open label depression trials have been remarkable, exceeding expectations and we are pleased to announce the completion of dosing in our landmark Phase 2B microdosing in depression trial. We anticipate sharing top-line results shortly.

MB22001 has already demonstrated in human clinical trials, substantial improvements in mood, sleep, anxiety, and overall quality of life, with sustained antidepressant effects observed six months after an eight-week treatment cycle. This innovative medicine targets the core symptoms of depression, including low energy, social withdrawal, disrupted sleep, and persistent low mood.

As the most advanced take-home psychedelic medicine in late-stage clinical trials, MB22001’s sub-hallucinogenic microdose allows patients to safely integrate it into their daily lives, much like any other medication, without disruption.

We invite you to join us in championing a brighter future for mental health treatment.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Read More!